FDA Commissioner Scott Gottlieb said he expects to stay on the job through his Congressional testimony on the proposed FDA budget for fiscal 2020 on April 3 and will leave the agency two days later.
Speaking at a Brookings Institution forum, Gottlieb offered some insights as he prepares to leave the agency. He urged health insurance companies to “look beyond the next quarter” when considering covering biosimilars. If insurance plans begin embracing biosimilars, they’ll see prices come down in the long run because of competition, he said.
Gottlieb also said he regretted that he won’t be able to stay on to help steer over-the-counter drug reforms as they work their way through Congress and the agency.